Common Sense Oncology shared a post on LinkedIn:
“Common Sense Oncology and EORTC – European Organisation for Research and Treatment of Cancer have jointly published recommendations for randomized clinical trials aimed at improving patient understanding of the impacts of cancer medicines on health-related quality of life in the latest issue of The Lancet Oncology.
The policy review by Ian Tannock, Madeline Pe, and collaborators provides recommendations for the evaluation of health-related quality of life (HRQoL) in randomized controlled trials that investigate the efficacy of new systemic treatment for people with advanced cancer.
Although there are existing standards for measuring HRQoL endpoints, the question often remains: which type of analysis best facilitates clinicians in discussing the HRQoL benefit of a cancer therapy in a way that is easily understood by patients.
The paper recommends using responder criteria to report HRQoL data. This means evaluating the proportion of patients who experience significant improvement or deterioration in their quality of life, making the data more relevant and understandable for both clinicians and patients.
For more information, read the joint press release from CSO and EORTC as well as the full paper in The Lancet Oncology.”
More posts featuring Common Sense Oncology.